查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011535

脑膜炎双球菌疫苗市场：全球市场预测（依疫苗类型、年龄层、剂型、通路、最终用户和适应症划分）－2026-2032年

Meningococcal Vaccines Market by Vaccine Type, Age Group, Formulation, Distribution Channel, End User, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脑膜炎双球菌疫苗市值将达到 66 亿美元，到 2026 年将成长至 71.6 亿美元，到 2032 年将达到 137.4 亿美元，复合年增长率为 11.02%。

主要市场统计数据
基准年 2025 66亿美元
预计年份：2026年 71.6亿美元
预测年份 2032 137.4亿美元
复合年增长率 (%) 11.02%

公共卫生、临床和技术趋势正在重塑脑膜炎双球菌疫苗利益相关人员的策略重点。

全球脑膜炎双球菌疫苗格局正处于关键时刻，其发展受到抗原设计进步、免疫接种建议不断扩展以及公共卫生重点转变的影响。临床开发正超越​​传统的多醣体疫苗策略，结合疫苗和蛋白质次单元平台能够提供更持久的保护效力，并适用于不同年龄层。同时，监管流程也在日趋成熟，能够在疫情爆发期间快速审查疫苗，并促进研发人员、监管机构和公共卫生机构之间更紧密的合作。这些进展凸显了整合策略的重要性，这些策略涵盖临床开发、生产规模化、供应链稳定性以及与支付方的合作。

科学突破、监管柔软性和采购创新如何协同加速脑膜炎双球菌疫苗计画的能力和应对力。

近期技术和政策的变革正在改变脑膜炎双球菌疫苗的研发、生产和供应方式。分子抗原设计和偶联化学的进步使得候选疫苗能够覆盖更广泛的血清型，并提高免疫抗原性。同时，佐剂科学和蛋白质工程也拓展了诱导各年龄层产生强效免疫反应的工具。这些科学进步与生产技术的创新相辅相成，例如模组化和一次性使用系统，这些技术缩短了前置作业时间，并实现了区域范围内的灵活生产。

评估 2025 年关税变化对製造选择、筹资策略、供应链韧性和临床供应物流的多方面影响。

2025年关税调整的实施对脑膜炎双球菌疫苗生态系统产生了多方面的影响，直接和间接地影响供应链、生产决策和筹资策略。关税推高了进口原料（包括特殊试剂、一次性耗材和成品疫苗）的成本，促使生产商和采购商重新评估筹资策略。为此，一些生产商正在扩大其区域製造地或与供应商谈判长期合同，以保护其业务免受关税波动的影响。此类调整往往有利于拥有整合供应链和有资金投资本地生产能力的企业。

透过分析每种疫苗类型、年龄层、配方、分销管道、最终用户和适应症的需求驱动因素及其临床和商业性影响，我们可以帮助制定有针对性的策略。

为了深入了解市场，有必要专注于影响需求趋势、临床策略和商业化路径的几个细分领域。我们将根据疫苗类型，分析结合疫苗、多醣体疫苗和蛋白质次单元疫苗的市场格局。每种疫苗都有不同的免疫学特性，对目标族群的适用性也各不相同。结合疫苗因其免疫记忆效应以及在儿童和青少年常规免疫接种计划中的效用而备受青睐。同时，多醣体製剂在应对特定集体爆发或作为补充手段方面仍可能保持其重要性。蛋白质次单元疫苗候选产品因其广泛的交叉保护作用和更好的耐受性而备受关注，有望扩大其在成人和老年人群中的应用。

本研究探讨了世界各地不同的流行病学情况、基础设施成熟度和采购惯例如何影响疫苗的选择、供应和能力优先排序。

区域趋势对脑膜炎双球菌疫苗的临床优先事项、采购行为和营运需求有显着影响。在美洲，监测能力和已建立的免疫规划推动了对常规免疫接种计划的持续需求，但零星疫情和旅行相关暴露仍然会造成一些地区紧急需求。这些地区的医疗卫生系统强调整合采购机制以及国家免疫规划与地方采购负责人之间的协调。许多地区完善的低温运输基础设施和较高的疫苗接种率有利于多剂次和单剂次疫苗的推广，但仍有差异，需要製定因地制宜的分发策略。

分析竞争格局，其中科学差异化、製造灵活性和战略伙伴关係决定产品准入和长期专案成功。

脑膜炎球菌疫苗领域的竞争动态由成熟的疫苗生产商、新兴生物技术公司、契约製造和专业服务供应商共同构成​​。成熟的生产商凭藉其可靠的临床记录、广泛的监管核准和成熟的生产线保持优势，而新参与企业通常透过抗原创新、新型佐剂或灵活的生产能力来脱颖而出。策略伙伴关係和授权协议是加速获取互补能力（例如结合技术和区域填充和包装能力）的关键途径，从而加快有前景的候选疫苗上市速度。

为製造商、政策制定者和供应链领导者制定明确且优先的行动方案，将科学进步转化为扩充性、有韧性和公平的疫苗取得途径。

行业领导者应采取一系列优先行动，将科学进步转化为具有韧性和可及性的免疫接种计划。首先，将供应链风险评估纳入早期产品规划，以识别关键投入和上游工程中的薄弱环节，并在策略上适宜的情况下寻求多元化和本地化生产。其次，透过减少对低温运输的依赖，并设计便于在儿童、青少年、成人和老年人等不同人群中给药的製剂和剂型，使临床开发适应最终用户的实际情况。第三，与监管机构和公共卫生机构建立积极的合作关係，以简化应对感染疾病疫情的核准流程，并确保可预测的采购承诺。

一项高度透明且严谨的混合方法研究，将与专家的初步访谈与系统的二次文献综述相结合，得出了检验且可操作的见解。

本分析的调查方法确保了严谨的证据基础，具体做法是将结构化的原始研究与对同行评审文献、监管文件和公开监测报告的系统性回顾相结合。原始研究包括对免疫专案管理人员、临床研究人员、生产专家和采购负责人进行定性访谈，以了解实际情况和策略重点。二手资料包括科学文章、监管指导文件、临床试验註册资讯和技术报告，这些资料提供了有关产品特性、安全性概况和实施注意事项的资讯。

科学创新与营运韧性的融合，为透过有针对性的疫苗接种策略持续减少脑膜炎双球菌病菌感染奠定了基础。

总之，由于技术创新、政策框架的演变以及供应和采购方面的营运变革，脑膜炎双球菌疫苗的现状正处于一个转折点。结合疫苗技术、蛋白质次单元和生产方法的科学进步正在创造新的选择，以更好地满足不同年龄层和使用情境的需求。同时，不断完善的政策和实验性的采购措施使得应对集体爆发的措施更加灵活，并提高了公共卫生目标与商业性奖励的契合度。这些因素共同凸显了整合临床卓越性、供应链韧性和相关人员合作的综合策略的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 脑膜炎双球菌疫苗市场：依疫苗类型划分

  • 组合型
  • 多醣
  • 蛋白质次单元

第九章 脑膜炎双球菌疫苗市场：依年龄组别划分

  • 青年
  • 成人版
  • 老年人
  • 儿童

第十章：以剂型分類的脑膜炎双球菌疫苗市场

  • 多次给药
  • 单一剂量

第十一章 脑膜炎双球菌疫苗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 脑膜炎双球菌疫苗市场：依最终用户划分

  • 诊所
  • 医院
  • 研究机构
  • 疫苗接种中心

第十三章 脑膜炎双球菌疫苗市场：依适应症划分

  • 应对集体爆发
  • 常规疫苗接种
  • 旅行者疫苗接种

第十四章 脑膜炎双球菌疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 脑膜炎双球菌疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 脑膜炎双球菌疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国脑膜炎双球菌疫苗市场

第十八章：中国脑膜炎双球菌疫苗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bharat Biotech Ltd.
  • Bio-Med Private Ltd
  • GlaxoSmithKline PLC
  • Incepta Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • PT Bio Farma
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Taj Pharmaceuticals Limited
Product Code: MRR-430D42AA101A

The Meningococcal Vaccines Market was valued at USD 6.60 billion in 2025 and is projected to grow to USD 7.16 billion in 2026, with a CAGR of 11.02%, reaching USD 13.74 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.60 billion
Estimated Year [2026] USD 7.16 billion
Forecast Year [2032] USD 13.74 billion
CAGR (%) 11.02%

Contextualizing the evolving public health, clinical, and technological landscape that is reshaping strategic priorities for meningococcal vaccine stakeholders

The global landscape for meningococcal vaccines has entered a pivotal phase, shaped by advances in antigen design, expanded immunization recommendations, and evolving public health priorities. Clinical development has broadened beyond traditional polysaccharide approaches, with conjugate and protein subunit platforms offering improved durability of protection and suitability across diverse age groups. Concurrently, regulatory pathways have matured to accommodate accelerated reviews in outbreak contexts, prompting closer collaboration among developers, regulators, and public health agencies. These dynamics have elevated the importance of integrated strategies that span clinical development, manufacturing scale-up, supply chain security, and payer engagement.

As stakeholders reassess their long-term strategies, they must balance clinical performance with real-world delivery challenges. Vaccine developers are increasingly focused on attributes beyond efficacy, including thermostability, presentation formats that facilitate mass campaigns or routine schedules, and formulations designed for single-dose logistics. Health systems and immunization programs are prioritizing predictable supply and flexible procurement instruments, while research institutions emphasize surveillance to detect serogroup shifts. Together, these elements create a complex operational environment where cross-disciplinary coordination is essential for translating scientific progress into measurable reductions in meningococcal disease burden.

How scientific breakthroughs, regulatory agility, and procurement innovations are collectively accelerating capability and responsiveness in meningococcal vaccine programs

Recent technological and policy shifts are transforming how meningococcal vaccines are developed, manufactured, and delivered. Advances in molecular antigen design and conjugation chemistry have enabled candidates with broader serogroup coverage and improved immunogenicity, while adjuvant science and protein engineering have expanded the toolkit for eliciting robust immune responses across age cohorts. These scientific strides are complemented by innovations in manufacturing technologies, such as modular and single-use systems, which reduce lead times and support flexible production at regional scales.

On the policy front, public health authorities are increasingly adopting adaptive immunization policies informed by enhanced epidemiologic surveillance and modeling. This has shifted attention toward tailored strategies that consider local serogroup prevalence, population immunity profiles, and risk factors such as travel and mass gatherings. Simultaneously, procurement mechanisms are evolving; pooled purchasing, long-term purchase agreements, and advance market commitments are gaining traction as instruments for stabilizing supply and encouraging investment in capacity. Taken together, these transformative shifts are lowering technical and operational barriers, creating new opportunities to expand coverage and respond more nimbly to outbreak pressures.

Assessing the multifaceted implications of 2025 tariff changes on manufacturing choices, procurement strategies, supply chain resilience, and clinical supply logistics

The introduction of tariff adjustments in 2025 has had multifaceted implications for the meningococcal vaccine ecosystem, with direct and indirect effects on supply chains, manufacturing decisions, and procurement strategies. Tariffs raise the cost of imported inputs such as specialized reagents, single-use consumables, and finished vaccine shipments, prompting manufacturers and purchasers to reassess sourcing strategies. In response, some producers are expanding regional manufacturing footprints or negotiating longer-term supplier agreements to insulate operations from tariff volatility. Such adjustments tend to favor organizations with integrated supply chains or the capital to invest in localized capacity.

Moreover, tariffs influence the calculus of public-sector procurement. Health authorities and global partners reassess total landed costs and may adjust procurement schedules or prioritize domestically produced options when feasible. These dynamics also affect clinical trial supply logistics, where import duties on investigational materials can increase operational complexity. Importantly, tariffs have prompted closer collaboration between manufacturers and policymakers to design mitigation strategies, including tariff exemptions for essential health commodities, harmonized classification of vaccine components, and support for scaling regional fill-and-finish capabilities. While tariffs create short-term cost pressures, they also catalyze structural shifts in supply chain resilience and localization strategies that stakeholders can leverage to reduce future disruption risks.

Dissecting demand drivers and clinical-commercial implications across vaccine type, age cohort, formulation, distribution channel, end user, and indication to inform targeted strategies

A granular understanding of the market requires attention to several segmentation dimensions that affect demand dynamics, clinical strategy, and commercialization pathways. Based on Vaccine Type, the landscape is studied across Conjugate, Polysaccharide, and Protein Subunit approaches, each offering distinct immunological profiles and suitability for target populations. Conjugate vaccines continue to be favored for their immunological memory and utility in routine pediatric and adolescent schedules, while polysaccharide formulations may retain relevance for specific outbreak responses or as complementary tools. Protein subunit candidates are attracting interest where broad cross-protection and improved tolerability support expanded use in adults and older age groups.

Based on Age Group, analysis covers Adolescent, Adult, Geriatric, and Pediatric cohorts, recognizing that immunization strategies and clinical endpoints vary by life stage. Pediatric programs emphasize early-life protection and integration with routine schedules, adolescents represent a key group for catch-up and school-based campaigns, adults and geriatric populations require tailored immunogenicity and safety assessments, and travelers or occupational groups create targeted demand. Based on Formulation, the landscape examines Multi Dose and Single Dose presentations, with single-dose formats enhancing campaign efficiency and multi-dose vials offering cost advantages but requiring careful cold-chain and safety safeguards. Based on Distribution Channel, the study considers Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways, acknowledging shifting patient behaviors, digital prescribing trends, and the role of hospital systems in centralized immunization delivery. Based on End User, focus areas include Clinics, Hospitals, Research Institutes, and Vaccination Centers, each with distinct procurement practices, storage capabilities, and administration workflows. Based on Indication, the market is examined across Outbreak Response, Routine Prophylactic, and Traveler Immunization use cases, which guide product selection, regulatory obligations, and deployment timelines. Together, these segmentation lenses provide a nuanced framework for aligning clinical development priorities, commercialization strategies, and public health planning.

Exploring how distinct epidemiology, infrastructure maturity, and procurement practices across global regions influence vaccine selection, delivery, and capacity priorities

Regional dynamics materially shape clinical priorities, procurement behaviors, and operational requirements for meningococcal vaccines. In the Americas, surveillance capacity and established immunization programs drive consistent demand for routine schedules, while episodic outbreaks and travel-related exposures continue to create pockets of urgent need. Health systems in this region place emphasis on integrated procurement mechanisms and coordination between national immunization programs and subnational purchasers. Cold-chain infrastructure and high vaccination coverage in many settings facilitate deployment of both multi-dose and single-dose formats, yet disparities remain that require tailored distribution strategies.

Europe, Middle East & Africa exhibits wide heterogeneity: high-income parts of Europe maintain rigorous vaccine monitoring and policy processes that prioritize long-term protection, whereas regions within the Middle East and Africa contend with variable surveillance infrastructure, lower baseline coverage in some areas, and periodic large-scale outbreaks that necessitate rapid mass vaccination responses. Capacity building for laboratory confirmation and serogroup surveillance is a priority across several jurisdictions. The Asia-Pacific region presents a combination of large-scale routine immunization platforms, growing domestic manufacturing ambitions, and diverse epidemiologic profiles. Urban concentration and increasing travel create ongoing demand for traveler immunization, while investments in regional manufacturing and regulatory harmonization are enhancing supply security. Collectively, these regional patterns inform how stakeholders prioritize product portfolios, manufacturing investments, and public-private collaboration.

Mapping the competitive landscape where scientific differentiation, manufacturing agility, and strategic partnerships determine product access and long-term program success

Competitive dynamics in the meningococcal vaccine arena are shaped by a mixture of established vaccine manufacturers, emerging biotechnology firms, contract manufacturers, and specialized service providers. Incumbent manufacturers maintain advantages through proven clinical track records, broad regulatory approvals, and established production lines, while newer entrants frequently differentiate on antigen innovation, novel adjuvants, or manufacturing agility. Strategic partnerships and licensing arrangements have become a primary vehicle for accelerating access to complementary capabilities, such as conjugation expertise or regional fill-and-finish capacity, enabling faster route-to-market for promising candidates.

In parallel, contract manufacturing organizations and fill-and-finish specialists play an increasingly strategic role by offering scalable, geographically distributed capacity that can mitigate single-point failures. Collaboration between commercial teams and public health purchasers is also evolving; outcomes-based contracting, long-term supply agreements, and coordinated technology transfers are mechanisms being used to secure sustained access. Finally, alliances between academic researchers and industry accelerate translational work, particularly where novel protein subunit approaches require iterative clinical evaluation. Overall, organizations that combine scientific differentiation with flexible manufacturing, robust regulatory planning, and proactive stakeholder engagement are positioned to capture the most durable value.

Clear, prioritized actions for manufacturers, policymakers, and supply chain leaders to convert scientific progress into scalable, resilient, and equitable vaccine access

Industry leaders should adopt a prioritized set of actions to convert scientific advances into resilient, accessible immunization programs. First, integrate supply chain risk assessments into early product planning to identify critical inputs and upstream vulnerabilities, then pursue diversification or localized production where strategic. Second, align clinical development with end-user operational realities by designing formulations and delivery formats that reduce cold-chain reliance and facilitate administration across pediatric, adolescent, adult, and geriatric settings. Third, cultivate proactive engagement with regulators and public health agencies to streamline approval pathways for outbreak responses and to secure predictable procurement commitments.

Additionally, pursue scalable manufacturing models that leverage modular facilities and contract partners to accelerate capacity expansion without overextending capital commitments. Strengthen surveillance partnerships with public health laboratories and academic centers to detect serogroup shifts and to inform adaptive immunization strategies. Finally, invest in evidence generation that demonstrates real-world effectiveness, safety across age cohorts, and health economic value to support inclusion in immunization schedules and to facilitate payer negotiations. By executing these priorities in parallel, organizations can improve their ability to respond to outbreaks, expand routine protection, and sustain reliable supply.

A transparent and rigorous mixed-methods research approach combining primary expert interviews and systematic secondary review to produce validated, actionable insights

The research methodology underpinning this analysis combined structured primary research with systematic review of peer-reviewed literature, regulatory documents, and publicly available surveillance reports to ensure a rigorous evidence base. Primary research included qualitative interviews with immunization program leaders, clinical investigators, manufacturing experts, and procurement specialists to capture operational realities and strategic priorities. Secondary sources comprised scientific publications, regulatory guidance documents, clinical trial registries, and technical reports that inform product attributes, safety profiles, and implementation considerations.

Data synthesis followed a transparent process: findings from interviews and document reviews were triangulated to identify consistent themes and to highlight areas of divergence. Quality assurance steps included source validation, cross-referencing of clinical and regulatory data, and expert review by independent advisors with domain experience in vaccinology, public health policy, and pharmaceutical manufacturing. Throughout, ethical standards and confidentiality protocols were maintained for interview subjects, and analytical assumptions were explicitly documented to ensure reproducibility of insights and to support evidence-based decision-making.

Converging scientific innovation and operational resilience form the foundation for sustained progress in reducing meningococcal disease through targeted vaccine strategies

In summary, the meningococcal vaccine landscape is at an inflection point driven by technical innovation, evolving policy frameworks, and operational shifts in supply and procurement. Scientific advances in conjugate technologies, protein subunits, and manufacturing methodologies are creating new options that better match the needs of diverse age cohorts and use cases. At the same time, policy evolution and procurement experimentation are enabling more adaptive responses to outbreaks and improving alignment between public health goals and commercial incentives. These converging factors underscore the importance of integrated strategies that combine clinical excellence with supply chain resilience and stakeholder collaboration.

Going forward, success will hinge on the ability of stakeholders to translate immunologic improvements into products that are logistically feasible and economically viable for routine programs and emergency responses. Investments in regional capacity, strategic partnerships, and surveillance infrastructure will be critical to sustaining long-term access and ensuring that clinical gains translate into measurable reductions in disease burden. For decision-makers, the imperative is to pursue coordinated planning across development, manufacturing, regulation, and delivery so that innovations reach populations in need with speed, reliability, and equity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Meningococcal Vaccines Market, by Vaccine Type

  • 8.1. Conjugate
  • 8.2. Polysaccharide
  • 8.3. Protein Subunit

9. Meningococcal Vaccines Market, by Age Group

  • 9.1. Adolescent
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Meningococcal Vaccines Market, by Formulation

  • 10.1. Multi Dose
  • 10.2. Single Dose

11. Meningococcal Vaccines Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Meningococcal Vaccines Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Research Institutes
  • 12.4. Vaccination Centers

13. Meningococcal Vaccines Market, by Indication

  • 13.1. Outbreak Response
  • 13.2. Routine Prophylactic
  • 13.3. Traveler Immunization

14. Meningococcal Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Meningococcal Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Meningococcal Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Meningococcal Vaccines Market

18. China Meningococcal Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Astellas Pharma Inc.
  • 19.6. AstraZeneca PLC
  • 19.7. Bharat Biotech Ltd.
  • 19.8. Bio-Med Private Ltd
  • 19.9. GlaxoSmithKline PLC
  • 19.10. Incepta Pharmaceuticals Ltd.
  • 19.11. Merck & Co., Inc.
  • 19.12. Novartis AG
  • 19.13. Pfizer Inc.
  • 19.14. PT Bio Farma
  • 19.15. Sanofi S.A.
  • 19.16. Serum Institute of India Pvt. Ltd.
  • 19.17. Taj Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)